Alto Neuroscience, Inc.
corporate_fare Company Profile
Alto Neuroscience, Inc. (NYSE:ANRO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for ANRO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-12, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ANRO spans 10-Q, 8-K, 424B5, DEF 14A.
Recent high-impact activity:
- Alto Neuroscience Q2 2026: $27.6M Net Loss, CFO Adopts 10b5-1 Plan
- Alto Neuroscience Expands ALTO-207 Program with New Phase 3 Trial Amid Q2 Loss
- $94M Stock Offering at 7% Discount to Fund Key Drug Trial
- Alto Neuroscience prices a $100M public offering at $26.48 per share to fund Phase 3 trials of ALTO-207
- Alto Neuroscience Raises $100M in Public Offering to Fund Phase 3 Trial and Extend Cash Runway
Financial Snapshot
Short Interest & Short Volume
9.08 days to coverFINRA reported short interest of 4,174,082 shares in ANRO as of the September 15, 2026 settlement, a 8.8% increase from the prior period — about 9.1 days to cover at its recent average daily volume. On October 2, 2026, 79.3% of ANRO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ANRO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-14.
Public Offering Completed · Strategic Use of Proceeds
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →